Articles Tagged with

statement

Home / statement

American Academy of Pain Medicine Rejects “Fake News”

The American Academy of Pain Medicine stands by our colleagues in the AMA to condemn the statements by President Trump referenced in a recent New York Times article, regarding accusations of profit and self-interest in taking care of patients during the pandemic. Physicians have put themselves and their families at risk in executing their Hippocratic oath to treat patients despite the personal risks. In addition to balancing the treatment of acute and chronic pain with the need to keep our patients safe from COVID, a majority of our members are anesthesiologists, many of whom are working in hospitals to take care of the critically ill as well. At AAPM we support our members’ selfless dedication to our patients, despite the risks of personal harm.

AAPM Signs AMA Letter Discouraging CMS Expansion of NPP Services in IRF Settings

The American Medical Association (AMA), AAPM, and other leading health care organizations released a letter on June 11, 2020, responding to a proposal by the Centers for Medicare and Medicaid Services (CMS) that would allow non-physician providers (NPPs) to provide services at Inpatient Rehabilitation Facilities (IRFs) that are currently limited to rehabilitation physicians. The letter discourages the expansion by emphasizing its potential to “undermine delivery of and access to physician-led team-based care” in IRFs. Full letter.

AAPM Statement on Racism in Health Care

The American Academy of Pain Medicine condemns racism and acknowledges its heavy toll on public health. Racial and ethnic disparities in pain treatment and pain treatment outcomes have been widely documented. AAPM is committed to working with its members and the health care community at large to eradicate these disparities, so that all health care professionals and persons seeking health care and pain care are safe, respected, and valued. 

American Pain Society

The American Academy of Pain Medicine (AAPM) is disheartened to learn of the dissolution of the American Pain Society (APS). Over the past nearly 40 years, AAPM has been fortunate to serve alongside APS in shared efforts to advance pain education, research, and advocacy. The closing of this long-standing organization is a loss for the entire pain community. AAPM offers its support to APS leaders, staff, and members, whom we remain committed to working with to advance multidisciplinary and patient-centered pain care.

AAPM Issues Updated Position Statement on Research into the Use of Cannabinoids for Medical Purposes

More than 30 states as well as Washington D.C. have legalized cannabis for medical purposes, making it more accessible than ever before to patients throughout the country, including patients suffering from chronic pain. However, major systematic reviews on the use of cannabinoids for chronic pain have yielded conflicting conclusions regarding their effectiveness and safety.

“The lack of high quality, evidence-based clinical research into the use of cannabinoids for chronic pain, leaves both clinicians and patients at a distinct disadvantage when weighing the risks and benefits of considering cannabinoids as a pain treatment,” says AAPM Scientific Review and Guidelines Committee Co-Chair, Michael D. Osborne, MD.

On May 30 the AAPM Board of Directors approved an updated position statement on research into the use of cannabinoids for medical purposes, urging FDA to reschedule cannabinoids from Schedule I to Schedule II in order to facilitate needed research into the medical effectiveness, substance toxicity, and overall safety of these products for the treatment of pain. Read the full position statement.

“AAPM promotes individualized, patient-centered pain care delivered by a multidisciplinary team and employing the wide variety of therapies available to improve patient function and reduce suffering. In order for cannabinoids to become a trusted part of the pain management tool kit, it is essential to conduct further research,” says AAPM Scientific Review and Guidelines Committee Co-Chair, Randall Brewer, MD. “We believe that rescheduling tetrahydrocannabinol, an active ingredient in marijuana, will be a critical step in facilitating the necessary research to determine the role of cannabinoids in the treatment of chronic pain.”

1 2
Pain Medicine Journal
Access to this page is restricted to members only! Not a mamber? Join Now!

Ask Us Anything. Anytime.

📝 Fill in your details and we’ll get back to you in no time.
AAPM

American Academy of Pain Medicine